Arie Belldegrun is Director of UroGen Pharma Ltd.. Currently has a direct ownership of 408,693 shares of URGN, which is worth approximately $6.86 Million. The most recent transaction as insider was on Sep 14, 2022, when has been sold 160,000 shares (Ordinary Shares) at a price of $5.0 per share, resulting in proceeds of $800,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 409K
0% 3M change
0% 12M change
Total Value Held $6.86 Million

Arie Belldegrun Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 14 2022
BUY
Exercise of conversion of derivative security
$800,000 $5.0 p/Share
160,000 Added 28.13%
408,693 Ordinary Shares
Aug 31 2022
BUY
Exercise of conversion of derivative security
$16,205 $5.0 p/Share
3,241 Added 1.29%
248,693 Ordinary Shares
Mar 24 2021
BUY
Exercise of conversion of derivative security
$16,205 $5.0 p/Share
3,241 Added 1.3%
245,452 Ordinary Shares

Also insider at

KRON
Kronos Bio, Inc. Healthcare
ALLO
Allogene Therapeutics, Inc. Healthcare
DNA
Ginkgo Bioworks Holdings, Inc. Healthcare
AB

Arie Belldegrun

Director
Princeton, NJ

Track Institutional and Insider Activities on URGN

Follow UroGen Pharma Ltd. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells URGN shares.

Notify only if

Insider Trading

Get notified when an Uro Gen Pharma Ltd. insider buys or sells URGN shares.

Notify only if

News

Receive news related to UroGen Pharma Ltd.

Track Activities on URGN